Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
Enregistré dans:
Auteurs principaux: | Peter J McCluskey, Richard Symes, Sophia Zagora, Denis Wakefield, Nitin Verma, Timothy Lee Tang Lee Say, Verlyn Yang, Jacob M Fingret, Christine Younan, Elisa Eleanor Cornish, Anthony Sammel, Deborah Speden |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7c6dbb33da9f4c9288fae3d87d75ca5b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
par: Kotaniemi K, et autres
Publié: (2011) -
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
par: Linda Cingolani, et autres
Publié: (2021) -
A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
par: Hendrik Rusche, et autres
Publié: (2021) -
Efficacy and safety of adalimumab in ankylosing spondylitis
par: Mounach A, et autres
Publié: (2014) -
Adalimumab for the treatment of Crohn’s disease
par: Andrea Cassinotti, et autres
Publié: (2008)